CD274 and neoplasm: Various studies were published comparing the complete response rate (CRR), objective response rate (ORR), and PFS and/or progressive-disease rate (PDR), based on tumor PD-L1 status in mRCC patients; the results showed that tumor PD-L1 positivity in patients receiving ICIs was associated with better ORR and prolonged PFS, suggesting PD-L1 as a possible positive predictive clinical biomarker [31,32].